Congress bets $100M on alternative protein—but who really wins?
S. 3528 — Producing Real Opportunities for Technology and Entrepreneurs Investing in Nutrition Act · Filed by Adam Schiff (D-CA) · 3 cosponsors · Introduced Dec 17, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes a federal research and development initiative to advance alternative protein production through bioprocessing and biomanufacturing—converting underutilized plant biomass into edible proteins and fats. It creates research centers of excellence, grants for commercial-scale facilities, workforce development programs, and directs the Department of Agriculture to develop a national strategy on protein security, with $100 million authorized over five years. The primary beneficiaries are agricultural researchers, biotech companies, farmers producing feedstock crops, and workers entering the alternative protein sector.
Why we flagged it
The bill is fundamentally a public investment in emerging agricultural biotechnology, combining research funding, infrastructure grants, and workforce development. While framed as food security and national strategy, it functions as targeted subsidy and R&D support for the alternative protein sector.
What the text implies
- The $10M minimum grant threshold may exclude smaller innovators and favor established biotech firms with existing infrastructure and grant-writing capacity.
- Requirement that entities be 'at least 51 percent owned and controlled by US citizens' may create barriers for international biotech partnerships or foreign-owned subsidiaries operating in the US.
The full analysis lists 5 implications of this text.
Who stands to gain
biotech companies specializing in alternative protein; agricultural research institutions and universities; food manufacturing equipment suppliers